NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DK-22-015 from the NIH Guide for Grants and Contracts. The Interventions that Address Structural Racism to Reduce Kidney Health Disparities Consortium aims to foster community-engaged intervention research to address structural racism to reduce health disparities among individuals living with kidney disease. The Consortium will consist of one Research Coordinating Center and multiple Intervention Sites (link to companion RFA) that will work collaboratively to develop, implement and evaluate meaningful interventions that aim to dismantle or mitigate the effects of structural racism to reduce kidney health disparities. This Funding Opportunity Announcement (FOA) invites applications for the Research Coordinating Center (RCC) that will lead, manage, and harmonize efforts for the Consortium. The specific activities of the RCC will include: 1) providing organization, management, and administrative support of Consortium activities; 2) providing research coordination, data management and data analyses for Consortium studies; and 3) fostering research collaborations and helping to build a community of investigators with skills to develop, implement, and disseminate effective, scalable, and sustainable interventions that address the structural drivers of kidney health disparities.
Funding Opportunity PAR-22-214 from the NIH Guide for Grants and Contracts. The overarching goal of this PAR is to support educational activities that complement and/or enhance the training of the clinical and research workforce, and bring awareness of Geroscience to members of the public, by supporting creative educational activities with a primary focus on the development and integration of basic, applied, translational, and clinical topics in Geroscience including: Curriculum or Methods Development, Courses for Skills Development, Research Experiences and Networking, Development of a Repository of Important Reviews and Opinion Pieces and Clinical Trials in Progress, Outreach and Creation of Lay Public Documents on Geroscience.
Notice NOT-AT-22-027 from the NIH Guide for Grants and Contracts
Notice NOT-AR-23-003 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-048 from the NIH Guide for Grants and Contracts. NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for the national opioid crisis. This research is part of the Helping to End Addiction Long-term (HEAL) Prevention Initiative, a portfolio of research focused on the prevention of opioid misuse and opioid use disorder funded under NIHs HEAL Initiative. The National Institute on Drug Abuse (NIDA) seeks to address the urgency and magnitude of the opioid crisis by developing and testing new or adapted interventions to prevent opioid misuse among patients served by community health centers (CHCs), and/or developing and testing implementation strategies for screening and referral to preventive interventions for misuse of opioids and other substances among patients served by CHCs. Research will be supported through exploratory/developmental phase awards (R61/R33) that may not exceed 5 years, allocating up to two years of funding for development of the project and up to four years for a full test of the research aims.
Funding Opportunity PAR-22-218 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Funding Opportunity PAR-22-219 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Funding Opportunity RFA-MH-22-185 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-20-525. The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.
Notice NOT-HS-22-021 from the NIH Guide for Grants and Contracts
Notice NOT-HS-22-020 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-045 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA.It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.
Notice NOT-HD-22-028 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-109 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-108 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-107 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-023 from the NIH Guide for Grants and Contracts. The accumulation of misfolded proteins in the brain is a key pathological feature shared by many neurodegenerative diseases that can result in dementia such as Alzheimers Disease, Lewy Body Diseases, Frontotemporal Degeneration, and cerebral amyloid angiopathy. Classical prion diseases such as Creutzfeldt-Jakob Disease are a rare family of neurodegenerative disorders that occur when the cellular prion protein (PrPC) undergoes structural conversion to a pathological form (PrPSc), which is usually triggered by its interaction with an infectious variant of the protein that forces the conformational change. Once this process is initiated, it becomes self-propagating until toxic aggregates accumulate within the CNS, leading to neuronal death. Because misfolded proteins of AD/ADRD have been reported to share some features with pathological prion protein at the structural level, it has thus been proposed that ADRD-relevant proteins such as Alpha, tau, beta-synuclein, and TDP-43 (among others) may exhibit prion-like behaviors that lead to toxic aggregate and tangle formation. The goal of this initiative is to promote studies that increase our understanding of the cellular and molecular mechanisms by which such prion-like conversion events occur and are propagated in AD/ADRD, as well as the downstream mechanisms that trigger neurotoxicity, pathological and circuit changes in the brain.
Notice NOT-NS-23-019 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-188 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-037 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-038 from the NIH Guide for Grants and Contracts